Sangui Biotech International, Inc.

HMSE:SBH Stock Report

Market Cap: €419.8k

Sangui Biotech International Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Thomas Striepe

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure16.2yrs
CEO ownershipn/a
Management average tenureno data
Board average tenureno data

Recent management updates

No updates

Recent updates

CEO Compensation Analysis

How has Thomas Striepe's remuneration changed compared to Sangui Biotech International's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$43k

Dec 31 2023n/an/a

-US$100k

Sep 30 2023n/an/a

-US$163k

Jun 30 2023n/an/a

-US$148k

Mar 31 2023n/an/a

-US$125k

Dec 31 2022n/an/a

-US$101k

Sep 30 2022n/an/a

-US$9k

Jun 30 2022US$83kUS$83k

-US$59k

Mar 31 2022n/an/a

-US$102k

Dec 31 2021n/an/a

-US$87k

Sep 30 2021n/an/a

-US$151k

Jun 30 2021US$80kUS$80k

-US$199k

Mar 31 2021n/an/a

-US$218k

Dec 31 2020n/an/a

-US$245k

Sep 30 2020n/an/a

-US$225k

Jun 30 2020US$75kUS$75k

-US$193k

Mar 31 2020n/an/a

-US$234k

Dec 31 2019n/an/a

-US$274k

Sep 30 2019n/an/a

-US$276k

Jun 30 2019US$68kUS$68k

-US$324k

Mar 31 2019n/an/a

-US$230k

Dec 31 2018n/an/a

-US$235k

Sep 30 2018n/an/a

-US$231k

Jun 30 2018US$19kUS$19k

-US$202k

Compensation vs Market: Insufficient data to establish whether Thomas's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.

CEO

Thomas Striepe (62 yo)

16.2yrs

Tenure

US$82,621

Compensation

Mr. Thomas Striepe has been the Chief Executive Officer of Sangui Biotech International, Inc. since April 8, 2008 and serves as its Chief Financial Officer. Mr. Striepe serves as the Vice President of Acco...

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/06/17 19:04
End of Day Share Price 2024/03/20 00:00
Earnings2024/03/31
Annual Earnings2023/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sangui Biotech International, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution